The rise in incidence of chronic
diseases like cancer has triggered the need of better treatment options.
Antibodies have the capacity to strengthen the immunity system to give it a
fighting chance.
Antibodies
Antibodies are Y-shaped proteins
produced within the immune system to thwart attacks from foreign bodies like
viruses. They neutralize these bodies by identifying their antigen and prevent
its expansion within the human body. It is also known as immoglobulin (Ig).
Monoclonal (mAbs) and polyclonal
(pAbs) antibodies are produced by biopharmaceutical and biotechnology companies
on a large scale to aid in treatment of cancer and blood disorders. These Ig’s
are created using the serum of animals. But recent technological breakthroughs
have resulted in the development of antibody-drug conjugates (ADCs).
View summary of this report, Click Here
Latest Developments
ADCs are advanced antibodies which
target foreign or cancerous cells without harming healthy cells. These drugs
contain a cytotoxic agent which targets only specified tumor cells. The U.S.
Food & Drug Administration (FDA) has approved Genentech’s Kadcyla to treat
metastatic breast cancer in 2011.
A novel technology developed by Sutro
Biopharma called cell-free protein synthesis can overcome the limitations of
cell gene expression systems. It can produce various versions of antibodies to
further the development of viable ADCs. The potency of these drugs depend on
the purity of mAbs. Other future trends in the market are molecules with
bispecific target binding and minimized antibody derived binding moieties.
Market Overview
The worldwide antibody production
market is anticipated to touch USD 23 billion by 2025, according to Grand View
Research, Inc. It is driven by the increasing demand of antibody therapeutics
by biopharmaceuticals. Development of advanced antibodies to treat rheumatic
heart disease, arthritis, and cancer is another driving factor spurring market
growth.
mAbs segment led the global market in
2016. Downstream processing generated huge revenues for the market in 2016. It
is expected to exhibit a significant growth rate over the forecast period due
to its utilization of chromatography devices and resins. Asia Pacific is
expected a robust growth rate over the forecast period due to favorable
regulations regarding antibody production. Key players are INTEGRA Biosciences
AG, Merck KGaA, Pall Corp., and Cellab GmbH.
Sample Request Of These Report : https://goo.gl/6Kc9km
ConversionConversion EmoticonEmoticon